Incident cancer risk after the start of aspirin use: Results from a Dutch population‐based cohort study of low dose aspirin users
Open Access
- 28 November 2013
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 135 (1), 157-165
- https://doi.org/10.1002/ijc.28634
Abstract
Observational and intervention studies suggest that low dose aspirin use may prevent cancer. The objective of this study was to investigate the protective effect of long term low dose aspirin use (≤100 mg daily) on cancer in general and site‐specific cancer among low dose aspirin users in the Dutch general population. We conducted a population‐based cohort study with detailed information on aspirin exposure and cancer incidence. Only incident (new) low dose aspirin users, who were included in the linkage between PHARMO and the Eindhoven Cancer Registry (1998–2010) and free of cancer before the start of follow up were included. A Cox proportional hazard model with cumulative aspirin use as a time‐varying determinant was used to obtain hazard ratios (HR). Duration of aspirin use amongst 109,276 incident low dose aspirin users was not associated with a decreased risk of any of the site‐specific cancers or cancer in general (adjusted HR per year of aspirin use for all cancers: 1.02, 95% confidence interval [CI] 1.00–1.04, HR of >6 years aspirin use compared to <2 years: 1.17, 95% CI 1.02–1.34). After adjusting for current and past aspirin use, 2–6 years of low dose aspirin use was associated with a reduced colorectal cancer risk compared to 6 years aspirin use 0.95, 95% CI 0.60–1.49). Our results do not support the primary prevention of cancer among long term aspirin users.Keywords
This publication has 27 references indexed in Scilit:
- Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer SurvivalNew England Journal of Medicine, 2012
- Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trialsLancet, 2012
- Aspirin and cancer risk: a quantitative review to 2011Annals of Oncology, 2012
- Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialThe Lancet, 2012
- Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up studyDiabetologia, 2011
- Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studiesEuropean Journal of Epidemiology, 2010
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Using prescription claims data for drugs available over‐the‐counter (OTC)Pharmacoepidemiology and Drug Safety, 2007
- Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal CancerJAMA, 2005
- Low-Dose Aspirin in the Primary Prevention of CancerJama-Journal Of The American Medical Association, 2005